Economic Burden of Non-Alcoholic Steatohepatitis with Significant Fibrosis in Thailand

Pochamana Phisalprapa

Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

Ratthanon Prasitwarachot

Department of Pharmacy Technicians, Sirindhorn College of Public Health Suphanburi, Suphanburi

Chayanis Kositamongkol

Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

Pranaidej Hengswat

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

Weerachai Srivanichakorn

Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

Chaiwat Washirasaksiri

Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

Sombat Treeprasertsuk

Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, Thai Red Cross, Bangkok

Phunchai Charatcharoenwitthaya

Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok

Nathorn Chaiyakunapruk (✉ nathorn.chaiyakunapruk@utah.edu)

Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT

Research Article

Keywords: Non-alcoholic steatohepatitis, NASH, Significant fibrosis, Economic burden, Cost of illness, Prevalence, Thailand

Posted Date: December 23rd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-129625/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on March 25th, 2021. See the published version at <https://doi.org/10.1186/s12876-021-01720-w>.

Abstract

Background: Non-alcoholic steatohepatitis (NASH) has been recognised as a significant form of chronic liver disease and a common cause of cirrhosis and hepatocellular carcinoma, resulting in a considerable financial burden on healthcare resources. Currently, there is no information regarding the economic burden of NASH in low- and middle-income countries (LMICs). The aim of this study was to estimate the economic burden of NASH in Thailand as a lesson learned for LMICs.

Methods: To estimate the healthcare costs and prevalence of NASH with significant fibrosis (fibrosis stage ≥ 2) in the general Thai population, an eleven-state lifetime horizon Markov model with 1-year cycle length was performed. The model comprised Thai population aged 18 years and older. The cohort size was based on Thailand Official Statistic Registration Systems. The incidence of NASH, transitional probabilities, and costs-of-illness were based on previously published literature, including systematic reviews and meta-analyses. The age-specific prevalence of NASH was based on Thai NASH registry data. Costs were expressed in 2019 US Dollars (\$). As we undertook analysis from the payer perspective, only direct medical costs were included. All future costs were discounted at an annual rate of 3%. A series of sensitivity analyses were performed.

Results: The estimated total number of patients with significant NASH was 2.9 million cases in 2019, based on a NASH prevalence of 5.74%. The total lifetime cost of significant NASH was \$15.2 billion (\$5,147 per case), representing approximately 3% of the 2019 GDP of Thailand. The probabilistic sensitivity analysis showed that the lifetime costs of significant NASH varied from \$11.4 billion to \$18.2 billion.

Conclusions: The economic burden associated with NASH is substantial in Thailand. This prompts clinicians and policy makers to consider strategies for NASH prevention and management.

Background

The excess accumulation of fat in the liver in patients without other causes such as excessive alcohol consumption or viral hepatitis is recognised as non-alcoholic fatty liver disease (NAFLD)[1]. It is a spectrum of diseases comprising two distinct conditions: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH)[2]. The latter is a severe form in which the steatosis is accompanied by lobular inflammation and hepatocyte ballooning that can progress to liver fibrosis, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma (HCC) and other liver-related mortalities[3–6]. These are the causes of the mounting number of hospital admissions, which are likely to continue to increase every year.

NASH is now considered the second most common indication for liver transplantation in the United States after chronic hepatitis C[7]. A number of previous studies have revealed that patients with NASH are at high risk for advanced liver disease[8–10], and those with significant fibrosis have a significantly higher risk of overall mortality than the general population[11]. A study on the epidemiology and disease

burden of non-alcoholic steatohepatitis suggested that NASH can affect 3–5% of the global population, with minor variations at the country-specific level[12]. A study focusing on the economic impact of NASH in Hong Kong suggested that the projected cost of NASH over 20 years would be \$1.32 billion, at \$257 per-person year[13], while a study on the lifetime cost of advanced NASH in the United States demonstrated that the condition costs a total of \$96.18 billion, at \$139,724 per patient[14].

In Thailand, several studies have calculated the incidence and prevalence of NAFLD. Previous studies showed that the prevalence of NAFLD varied from 24.58–67% depending on patients' underlying diseases[15–18]. However, information concerning the cost of illness of NASH—particularly NASH with significant fibrosis—is still limited in Thailand as well as in other low- and middle-income countries (LMICs). Certainly, an understanding of the economic burden of NASH in Thailand might be useful in helping policy makers with the development of strategies to manage this disease, which is likely to become a significant health issue in the near future. Therefore, this study set out to estimate the economic burden of NASH with significant fibrosis (fibrosis stage ≥ 2), using Thailand as an example of an LMIC.

Methods

Description of model

A Markov model, which was built in Microsoft Excel, was adapted from a study conducted by Chongmelaxme *et al.*[19] to estimate the health care costs and prevalence of NASH with significant fibrosis (fibrosis stage 2 and higher) in Thailand. The model consisted of the normal state and the ten other health states, namely, no fibrosis (F0), fibrosis stage 1 (F1), fibrosis stage 2 (F2), fibrosis stage 3 (F3), compensated cirrhosis or fibrosis stage 4 (F4), decompensated cirrhosis, HCC, liver transplantation (LT), post-liver transplantation (post-LT), and death. The model was developed adhering to the natural history of the disease, which progressively worsens to more severe states, and regression was allowed only from F0 to normal, F1 to F0, F2 to F1, F3 to F2, and F4 to F3 (Fig. 1). The model comprised the Thai population aged 18 years and older. In the analysis, the population in each age cohort entered the model at the normal state, and in the next cycle, they either remained in this state or transited to fibrosis stage 0 or death. The annual cycle length and a lifetime horizon were used in the model. The size of the population of each age group was based on Thailand Official Statistic Registration Systems, and the age-specific mortality rate (ASMR) was based on Global Health Observatory data from the World Health Organization[20, 21]. This model was performed from a payer perspective. All costs were discounted at the rate of 3%, in accordance with the recommendations of the Thai Health Technology Assessment (HTA) guidelines[22].

Input parameters

Overall, the input parameters were based on a literature review and country-specific data sources. All input parameters are detailed in (Table 1). The prevalence of NAFLD in the general Thai population was

pooled from previously published local studies[16–18, 23], and the age-specific prevalence of NASH with significant fibrosis was calculated from the NASH registry data of Siriraj Hospital, Mahidol University, and previous publications[24, 25] (see appendix 1 and 2). The transitional probabilities were mainly based on the study of Chongmelaxme *et al.*[19], which was the previous, model-based, economic evaluation study in Thailand.

Transitional probabilities

The transitional probabilities for all fibrosis stages were obtained from a systematic review and meta-analysis estimating the rates of fibrosis progression[26]. The transitional probabilities from F4 to decompensated cirrhosis and to HCC were based on published articles[27–31], whereas that of patients experiencing liver transplantation was derived from country-specific studies[32–34]. The age-specific mortality rate (ASMR) of the Thai population[21] multiplied by the relative risks of mortality among NAFLD and cirrhosis patients[35] was used as the mortality rate. The mortality rate of HCC patients was derived from a study estimating the mortality rate of Thai patients with HCC[36]. Since data on the mortality rate of transplanted NASH patients are not available, this study applied the death rate associated with liver transplants and post-liver transplantation in chronic hepatitis B and C patients[37].

Costs

Since this study was conducted from a payer perspective, only the direct medical costs were estimated. A micro-costing method was utilised to estimate the cost of health care utilisation. The outpatient costs included outpatient medication care and laboratory testing, with NAFLD patients being assumed to visit an outpatient clinic four times a year[38]. The relevant costs were obtained from a costing database in Thailand[39]. The treatment costs only related to NAFLD and NASH. As the costs for compensated cirrhosis, decompensated cirrhosis, and HCC are not available, they were assumed to be the same as for hepatitis C patients and were adapted from a country-specific study[40]. All costs were adjusted using the Consumer Price Index and reported in 2019 US Dollars (1 US Dollar = 32.3 Thai Baht)[41, 42].

Analysis

The outcome measures were the first-year cost, the fifth-year cost and the lifetime cost for each age group. The prevalence and incidence of NAFLD and the NASH with significant fibrosis population were estimated for 2019. A probabilistic sensitivity analysis (PSA) was performed to assess uncertainty and the impact of the base-case input parameters on the model outputs and their robustness (see appendix 5). The sensitivity analyses were conducted for all age groups.

Table 1
Input parameters, values, and data sources

Parameters	Base-case values	SE	References
Prevalence (NAFLD) in general population			
Age 18–39	0.353	0.013	[16–18, 23]
Age 40–59	0.348	0.002	[16–18, 23]
Age 60+	0.244	0.004	[16–18, 23]
Prevalence (NASH with significant fibrosis) in NAFLD			
Age 18–29	0.183	0.009	[24, 25]
Age 30–39	0.224	0.011	[24, 25]
Age 40–49	0.169	0.009	[24, 25]
Age 50–59	0.164	0.008	[24, 25]
Age 60–69	0.152	0.008	[24, 25]
Age 70–79	0.090	0.005	[24, 25]
Age 80+	0.090	0.005	[24, 25]
Transitional probabilities			
Progression			
Normal > F0	0.00140		[14]
Age 18–39	0.00407		
Age 40–59	0.00515		
Age 60–89	0.00150		
Age 90+			
F0 > F1	0.090	0.026	[26]
F1 > F2	0.140	0.036	[26]
F2 > F3	0.070	0.020	[26]
F3 > F4/CC	0.080	0.020	[26]
F4 > DC	0.060	0.010	[26]

CC compensated cirrhosis, *DC* decompensated cirrhosis, *F0* fibrosis stage 0/ no fibrosis, *F1* fibrosis stage 1, *F2* fibrosis stage 2, *F3* fibrosis stage 3, *F4* fibrosis stage 4, *HCC* hepatocellular carcinoma, *LT* liver transplantation, *NAFLD* non-alcoholic fatty liver disease, *NASH* non-alcoholic steatohepatitis, *Post-LT* post-liver transplantation, *SE* standard error

Parameters	Base-case values	SE	References
F4 > HCC	0.030	0.012	[27, 28]
DC > HCC	0.030	0.01173	[28–31]
DC > LT	0.0003	0.00002	[32–34]
HCC > LT	0.0016	0.00008	[32, 33]
HCC > Death	0.4490	0.02959	[21, 36]
LT > post-LT	0.7993	NA	
LT > Death	0.2007	0.01024	[37, 43]
Post-LT > Death	0.0653	0.00333	[37, 43]
Regression			
F0 > normal			Assumption
F1 > F0	0.080	0.026	[26]
F2 > F1	0.190	0.059	[26]
F3 > F2	0.200	0.087	[26]
F4 > F3	0.120	0.023	[26]
Direct medical costs (\$)			
NAFLD	88	11	[39]
NASH	89	11	[39]
CC	2121	271	[40]
DC	3916	499	[40]
HCC	4787	622	[40]
LT	18703	2298	[40]
Post-LT	2908	371	[40]
<i>CC</i> compensated cirrhosis, <i>DC</i> decompensated cirrhosis, <i>F0</i> fibrosis stage 0/ no fibrosis, <i>F1</i> fibrosis stage 1, <i>F2</i> fibrosis stage 2, <i>F3</i> fibrosis stage 3, <i>F4</i> fibrosis stage 4, <i>HCC</i> hepatocellular carcinoma, <i>LT</i> liver transplantation, <i>NAFLD</i> non-alcoholic fatty liver disease, <i>NASH</i> non-alcoholic steatohepatitis, <i>Post-LT</i> post-liver transplantation, <i>SE</i> standard error			

Results

Prevalence of NAFLD and NASH with significant fibrosis

The model estimated that the total NAFLD prevalence rate would be 32.17% and the total NASH with significant fibrosis prevalence rate would be 5.74% in 2019. It was found that the 18–39 age group would have the highest prevalence rate, with 35.12% and 7.14% for NAFLD and NASH with significant fibrosis, respectively. In 2019, of the total NAFLD cohort, 17.84% of the cases were estimated to have NASH. Based on the Thailand population, our model predicted that the total number of adult patients with NAFLD would be 16.6 million, while the number of NASH patients with significant fibrosis would be 2.9 million in 2019. Additionally, about 50% of the NASH with significant fibrosis population in 2019 would comprise adults aged under 39 (Table 2).

Table 2
Prevalence of NAFLD and NASH with significant fibrosis in Thailand in 2019

Age group	Thai population size	NAFLD Prevalence	NAFLD Cohort	NASH with significant fibrosis Prevalence	NASH with significant fibrosis Cohort
18–39	20533776	35.12%	7212381	7.14%	1466099
40–59	19919412	34.49%	6869359	5.80%	1155851
60+	11136059	22.57%	2513210	3.05%	339981
total	51589247	32.17%	16594951	5.74%	2961931
NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis					

Estimated costs

We estimated the economic burden of NASH with significant fibrosis at the first-year, fifth year and over a lifetime. In the base-case analysis, the first-year costs would be \$886,664,483, the fifth-year costs would be \$886,376,246, and the total lifetime cost for NASH with significant fibrosis was projected to be \$15.2 billion or \$5,174 per case. On one hand, we found that the highest estimated lifetime cost per case would be for adults aged over 60, mounting to \$9,492 per patient, while the lowest cost per case would be in the 18–39 age cohort, at \$4,393 per case. In contrast, the lifetime cost of the population aged 18–39 would account for 42% of the total amount, whereas that of patients aged over 60 would account for 21% of the total (Table 3).

Table 3
Lifetime cost for NASH with significant fibrosis

Age group	Total cases	1st -year cost (\$)	5th -year cost (\$)	Lifetime cost (\$)	Lifetime cost per case (\$)
18–39	1466099	214323428	283001011	6440244930	4393
40–59	1155851	240136567	330194687	5577909108	4826
60+	339981	432204487	273180548	3227197465	9492
total	2961931	886664483	886376246	15245351503	5147

Sensitivity analysis

Probabilistic sensitivity analyses were conducted for the NASH with significant fibrosis patients and included all age groups. The results showed that the total cases varied from 2.94 million to 2.99 million in 2019. Moreover, the lifetime cost of NASH with significant fibrosis was found to be around \$15.2 billion, varying from \$11.4 billion to \$18.2 billion, with the lifetime cost per case averaging \$5,147, ranging from \$3,833 to \$6,150 (Table 4; Fig. 2a and 2b).

Table 4
Sensitivity analysis results

Age group	Total cases (Min-Max)	Lifetime cost (\$) (Min-Max)	Lifetime cost per case (\$) (Min-Max)
18–39	1466099 (1445077–1486251)	6440244930 (4804286359–7196682390)	4393 (3266–4934)
40–59	1155851 (1141140–1168039)	5577909108 (4103739487–6751636344)	4826 (3549–5849)
60+	339981 (336251–343547)	3227197465 (2461384957–4203115813)	9492 (7259–12418)
total	2961931 (2937772–2986282)	15245351503 (11369410803–18151434547)	5147 (3833–6150)

Discussion

This study showed that the estimated prevalence of NASH with significant fibrosis in the adult Thai population in 2019 would be 2.9 million cases, with an estimated cost of \$886,376,245 in the fifth year. The predicted lifetime cost of this liver condition would be \$15.2 billion, or \$5,174 per case, which represented approximately 3% of the 2019 GDP of Thailand[44].

The NAFLD prevalence of Thailand from our study is relatively higher than those for Africa, North America, Europe, and other Asian countries, but similar to those for South America and the Middle East[8]. As to NASH, the total estimated NASH prevalence rate of our study, 5.74% of the Thai population, is similar to the rates for Canada and the US (5.2%[45] and 5.3%[46], respectively). However, these rates are slightly higher than the global prevalence, which ranges between 3% and 5%[12]. Interestingly, compared with other Asian countries such as China (2.4%[46]), Japan (3.0%[46]) and Hong Kong (4.5%[13]), the estimated NASH prevalence rate for Thailand is higher. This higher prevalence may be influenced by differences in ethnicity, genetic composition, diets, and sedentary lifestyles[13, 47]; however, these contributing factors need to be explored further. Nevertheless, awareness of this high prevalence for Thailand is important because it could urge clinicians and policy makers to focus on, and prepare for, the significant burdens presented by this disease.

In addition, when considered individual age groups, our results revealed that the lower-aged population has a higher prevalence of NAFLD and NASH. This could result from the older population having lower levels of fat deposits in the liver[48–50], which might be explained by the accumulated fat in the liver being burned out and becoming more fibrotic.

The total lifetime cost of NASH is substantially high, being equivalent to approximately 3% of the GDP of Thailand for 2019[44]. Focusing on each age group, we found that the lifetime cost per case for the younger age group was lower than that for the older group. Although the life expectancy of the older population is shorter than that of the younger population, the total lifetime cost per case is double that of the older population because more advanced diseases and higher progression rates are detected in the older population. Additionally, our results reveal the significant burden from NASH with significant fibrosis which is not only comparable with other significant health issues in Thailand such as alcohol consumption[51], smoking-related diseases[52], and obesity[53], but also higher in terms of economic burden resulting in the loss of health care resources and the country's economy.

Evidently, NASH with significant fibrosis cause the financial burden in both developing and developed countries. When comparing the total number of NASH cases and the financial burden revealed by our study with the corresponding data from developed countries[14], the costs and the number of cases in Thailand are lower. Nevertheless, they have a relatively high impact when considered in relation to the Thai economy.

It is important to note that our study estimated the burden from a payer perspective; hence, the costs of comorbidities, nonmedical costs, and societal costs of NASH were excluded from the model. This means that the economic burden of this disease is likely to have been markedly underestimated. If such parameters were included, the total costs of NASH would be larger because it would include the money spent by patients and their household members, as well as non-monetary losses, such as opportunity costs and lost income caused by illness.

In Thailand's context, health care services are still restricted, particularly human resources. This is a critical issue that must be considered. There is a significant human impact both in terms of the

healthcare professionals needed to deal with the disease and its consequences, and the loss of productive workers due to the illness. From our findings, around 3 million cases of NASH are predicted in 2019, yet there are only about 61,000 clinicians in Thailand[54]. This equates to a ratio of 1:50 for the doctors available to the number of NASH with significant fibrosis patients. There is an even lower ratio for the current number of hepatologists in Thailand (1:6,000 for NASH with significant fibrosis, and 1:130,000 for the general population, of whom about 6% may be diagnosed with NASH at any time). These ratios indicate that if a strategy is not developed to prevent NASH and its consequences, there will be insufficient numbers of medical professionals to provide adequate care to all patients and to effectively monitor the disease. As well, there will not be sufficient funding available to support patients from low-income households or those receiving healthcare via Thailand's Universal Coverage Scheme.

Thus, we should develop strategies to prevent NASH and its progressive state; otherwise, we will have to deal with the high costs of the disease. Screening is one possible strategy. It could enable early disease detection and promote early treatment, which would require relatively low funding. However, the cost of the screening strategy itself should be considered; therefore, a further study on screening costs is required.

Both NASH and its complications present huge burdens. For example, while cirrhosis and HCC need high-cost treatments, these diseases typically have poor outcomes. This study only considered NASH and its consequent diseases; when we take the real-world situation into account, there is much evidence that NASH is associated with comorbidities such as diabetes, obesity, dyslipidaemia, metabolic syndrome and cardiovascular diseases[7, 13, 55–57]. It may also lead to higher mortality and a higher financial burden for those with underlying diseases[9, 35]. Thus, predictions of the economic and financial burdens of the disease are important evidence in support of the need for preventative strategies, especially in developing countries.

To our knowledge, this is the first study to report the economic burden of NASH in LMICs. This study used Thailand as an example LMIC to reflect the increased burden of NASH in Southeast Asia. Our results are consistent with other studies that claimed that the burden of NAFLD and NASH are large and are ever increasing[13, 14, 45, 46]. The findings of the present study highlight that the prevention and treatment of NASH should be addressed by every LMIC in the world.

A key strength of this study was that its findings are likely to be valid as most of the input data used for the model were drawn from local sources. Secondly, the probabilistic sensitivity analysis that we conducted determined that the model was robust in its estimations of the costs of NASH with significant fibrosis.

There are some limitations to this study. Firstly, there is a lack of biopsy-proven NAFLD prevalence data for the Thai general population. We therefore pooled the prevalence of NAFLD from studies[16–18, 23] that had diagnosed the disease using imaging tests (ultrasonography) and transient elastography techniques (FibroScan). Because of their higher sensitivity, these information sources provided a more accurate disease prevalence than studies that had used liver function tests as the diagnostic method.

Moreover, the prevalence of NAFLD was consistent with the previous systematic review and meta-analysis in Asia[58][58]Secondly, there are no direct assessments of the incidence and prevalence of NASH in NAFLD patients, in view of the high risk of severe complications from liver biopsies conducted on NAFLD patients without any explicit risk of having NASH with significant fibrosis. Consequently, the NASH with significant fibrosis data were limited. Hence, we adopted the biopsy-proven and elastography-confirmed NASH with significant fibrosis prevalence to signify the proportion of NAFLD cases in Thailand[24, 25]. Thirdly, due to the unavailability of local or NASH-specific data, a few input parameters were retrieved from international studies, for instance, the transitional probabilities of fibrosis progression and regression. As well, the mortality rates of liver transplant and post-transplantation patients were adopted from the rates of Thai patients with hepatitis B and hepatitis C infections. Nevertheless, this information should be able to be used as representative data for the Thai population[19]. Lastly, our study did not consider other non-liver-related events which are known to associated with NASH such as cardiovascular diseases, obesity, etc. Thus, the total costs will increase if the treatment of those comorbidities are included.

Conclusions

NASH with significant fibrosis cause substantial economic burden in Thailand. This should prompt clinicians and policy makers to pay more attention in developing and implementing the effective strategies for the prevention and management of NASH.

List Of Abbreviations

ASMR Age specific mortality rate

CC Compensated cirrhosis

F0 Fibrosis stage 0/ no fibrosis

F1 Fibrosis stage 1

F2 Fibrosis stage 2

F3 Fibrosis stage 3

F4 Fibrosis stage 4

HCC Hepatocellular carcinoma

HTA Health Technology Assessment

LMICs Low- and middle-income countries

LT Liver transplantation

NAFLD Non-alcoholic fatty liver disease

NAFL Non-alcoholic fatty liver

NASH Non-alcoholic steatohepatitis

post-LT Post-liver transplantation

Declarations

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The protocol for this study was approved by the Siriraj Institutional Review Board (Si 540/2011). Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable

Availability of data and materials

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

Nathorn Chaiyakunapruk received an honorarium as advisory board for Intercept. All other authors have no competing interests to declare

Funding

The authors received no funding for this work.

Authors' contributions

PP, RP, PH, CK and NC contributed to the study concept and design, data acquisition, data analysis, data interpretation, manuscript drafting, critical revision of the manuscript, and the final review of the manuscript. WS and CW participated in the data acquisition, critical revision of the manuscript, and the final review of the manuscript. ST and PC participated in the study concept and design, data acquisition, data interpretation, critical revision of the manuscript, and the final review of the manuscript.

Acknowledgements

The authors thank Faculty of Medicine Siriraj Hospital, Mahidol University and Faculty of Medicine, Chulalongkorn University for the data and Miss Pinyapat Ariyakunaphan, research assistant, for collecting the data. The authors, also, gratefully thank David Park for editorial support with the manuscript.

References

1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67:328–57.
2. Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. *Curr Pharm Des*. 2019;24:4574–86.
3. Singh S, Kuftinec GN, Sarkar S. Non-alcoholic Fatty Liver Disease in South Asians: A Review of the Literature. *J Clin Transl Hepatol*. 2017;XX XX:1–6.
4. Balp M-M, Krieger N, Przybysz R, Way N, Cai J, Zappe D, et al. The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. *JHEP Reports*. 2019;1:154–61.
5. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. *Journal of Hepatology*. 2019;70:531–44.
6. Glen J, Floros L, Day C, Pryke R. Non-alcoholic fatty liver disease (NAFLD): Summary of NICE guidance. *The BMJ*. 2016;354.
7. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*. 2018;15:11–20.
8. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64:73–84.
9. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis. *Hepatology*. 2017;65:1557–65.
10. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology*. 2013;57:1357–65.
11. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwittaya P, et al. Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease HHS Public Access. *Gastroenterology*. 2015;149:389–97.
12. Povsic M, Wong OY, Perry R, Bottomley J. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). *Advances in Therapy*. 2019;36:1574–94.

13. Tampi RP, Wong VW, Wong GL, Shu SS, Chan HL, Fung J, et al. Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. *Hepatol Res*. 2020;50:1024–31.
14. Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States. *Hepatology*. 2019;69:564–72. doi:10.1002/hep.30254.
15. Phisalprapa P, Ujjin A, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, et al. Sa1050 Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Asian Individuals With Metabolic Syndrome. *Gastroenterology*. 2014;146:S-947.
16. Pitug B. Prevalence of nonalcoholic fatty liver disease (NAFLD) and correlation between prevalence of NAFLD and obesity in people living in borabue district, Mahasarakham province. *Mahasarakham Hosp J*. 2017;14:22–8.
17. Leelaprasert S. Prevalence and risk factor of Non alcoholic fatty Liver Disease using abdominal ultrasound in Krabi hospital. *Reg 11 Med J*. 2015;29:597–606.
18. Rattanangamkul M. The relation of non alcoholic fatty liver and metabolic syndrome in Thais. *Dhurakij Pundit University*; 2017.
19. Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. *Pharmacoeconomics*. 2019;37:267–78.
20. Official statistics registration systems. Population Statistics. <https://stat.bora.dopa.go.th/download/list.php>. Accessed 6 Dec 2019.
21. World Health Organization. Life tables:Thailand. World Health Organization. 2016. <https://apps.who.int/gho/data/node.country.country-THA?lang=en>. Accessed 20 Dec 2019.
22. Teerawattananon Y. Guidelines for Health Technology Assessment in Thailand (Second Edition). *J Med Assoc Thai*. 2014;97.
23. Thinkhamrop K, Khuntikeo N, Phonjitt P, Chamadol N, Thinkhamrop B, Moore MA, et al. Association between diabetes mellitus and fatty liver based on ultrasonography screening in the world's highest cholangiocarcinoma incidence region, Northeast Thailand. *Asian Pacific J Cancer Prev*. 2015;16:3931–6.
24. Saokaew S, Kanchanasuwan S, Apisarnthanarak P, Charoensak A, Charatcharoenwittaya P, Phisalprapa P, et al. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). *Liver Int*. 2017;37:1535–43.
25. Treeprasertsuk S, Piyachaturawat P, Soontornmanokul T, Wisedopas-Klaikaew N, Komolmit P, Tangkijavanich P. Accuracy of noninvasive scoring systems to assess advanced liver fibrosis in Thai patients with nonalcoholic fatty liver disease. *Asian Biomed*. 2016;10:S49–55.
26. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. *Clin Gastroenterol Hepatol*. 2015;13:643–54.

27. Hui J. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. *Hepatology*. 2003;38:420–7.
28. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. *Hepatology*. 2006;43:682–9.
29. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA-R, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology*. 2010;51:1972–8.
30. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier M-H, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology*. 2002;35:1485–93.
31. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J Gastroenterol Hepatol*. 2009;24:248–54.
32. Pachanee K, Wongphan T, Prakongsai P. Economic Evaluation and Budget Impact of Liver Transplantation among Thai Adults in Universal Health Insurance Coverage. 2016;25:908–19.
33. Subwongcharoen S, Treepongkaruna S-A, Leelawat K, Ruksakul K. Long-Term Outcome of Patients Undergoing Liver Transplantation at Rajavithi Hospital, Thailand. 2012.
34. Poovorawan K, Treeprasertsuk S, Thepsuthammarat K, Wilairatana P, Kitsahawong B, Phaosawasdi K. The burden of cirrhosis and impact of universal coverage public health care system in Thailand: Nationwide study. *Ann Hepatol*. 2015;14:862–8.
35. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology*. 2015;61:1547–54.
36. Leerapun A, Thaikruea L, Pisespongsa P, Chitapanarux T, Praisontarangkul O-A, Thongsawat S. Clinical features and prognostic factors for liver cancer from a referral center in northern Thailand. *J Med Assoc Thai*. 2013;96:531–7.
37. Kositamongkol P, Sanphasitvong V, Sirivatanauksorn Y, Pongpaibul A, Limsrichamrern S, Mahawithitwong P, et al. Outcome of Liver Transplantation in Hepatocellular Carcinoma Patients at Siriraj Hospital. *Transplant Proc*. 2017;49:1114–7.
38. Phisalprapa P, Supakankunti S, Charatcharoenwiththaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, et al. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. *Med (United States)*. 2017;96.
39. Riewpaiboon A. Standard cost lists for health technology assessment. Health Intervention and Technology Assessment Program (HITAP). 2011. <http://costingmenu.hitap.net/>. Accessed 6 Dec 2019.
40. Thongsawat S, Piratvisuth T, Pramoolsinsap C, Chutaputti A, Tanwandee T, Thongsuk D. Resource utilization and direct medical costs of chronic hepatitis C in Thailand: A heavy but manageable

- economic burden. *Value Heal Reg Issues*. 2014;3:12–8.
41. Consumer Price Index (CPI) of Thailand, Economic and Trade Indices Database (edit). Bureau of Trade and Economic Indices, Ministry of Commerce. 2017. <http://www.price.moc.go.th>. Accessed 6 May 2020.
 42. Bank of Thailand. Historical Foreign Exchange Rates. Bank of Thailand. 2017. https://www.bot.or.th/App/BTWS_STAT/statistics/ReportPage.aspx?reportID=123&language=eng. Accessed 8 May 2020.
 43. Sirivatanauksorn Y, Kongkaewpaisan N, Pongpaibul A, Limsrichamrern S, Mahawithitwong P, Kositamongkol P, et al. Outcomes of orthotopic liver transplantation in non-malignant end-stage liver diseases. In: *Transplantation Proceedings*. Elsevier USA; 2014. p. 778–81.
 44. World Bank. GDP Thailand (current US\$). 2016. <https://data.worldbank.org/country/TH> . Accessed 10 May 2020.
 45. Swain MG, Ramji A, Patel K, Sebastiani G, Shaheen AA, Tam E, et al. Burden of nonalcoholic fatty liver disease in Canada, 2019–2030: a modelling study. *C Open*. 2020;8:E429–36.
 46. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology*. 2018;67:123–33. doi:10.1002/hep.29466.
 47. Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. *J Hepatol*. 2017;67:862–73.
 48. Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. *Gerontology*. 2009;55:607–13.
 49. Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, et al. Nonalcoholic fatty liver disease and aging: Epidemiology to management. *World J Gastroenterol*. 2014;20:14185–204.
 50. Mak KM, Chu E, Lau KHV, Kwong AJ. Liver Fibrosis in Elderly Cadavers: Localization of Collagen Types I, III, and IV, α -Smooth Muscle Actin, and Elastic Fibers. *Anat Rec*. 2012;295:1159–67.
 51. Thavorncharoensap M, Teerawattananon Y, Yothasamut J, Lertpitakpong C, Thitiboonsuwan K, Neramitpitagkul P, et al. The economic costs of alcohol consumption in Thailand, 2006. *BMC Public Health*. 2010;10:323. <http://www.biomedcentral.com/1471-2458/10/323>.
 52. Bundhamcharoen K, Aungkulanon S, Makka N, Shibuya K. Economic burden from smoking-related diseases in Thailand. *Tob Control*. 2016;25:532–7.
 53. Pitayatiennanan P, Butchon R, Yothasamut J, Aekplakorn W, Teerawattananon Y, Suksomboon N, et al. Economic costs of obesity in Thailand: A retrospective cost-of-illness study. *BMC Health Serv Res*. 2014;14. doi:10.1186/1472-6963-14-146.
 54. The medical council of Thailand. Health workforce statistics. <https://www.tmc.or.th/pdf/st-tmc-02-07-20-001.pdf>. Accessed 30 Aug 2020.
 55. Gholam PM, Flancbaum L, MacHan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. *Am J Gastroenterol*. 2007;102:399–408.

56. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. *J Hepatol*. 2018.
57. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. *Clin Liver Dis*. 2016;20:205–14.
58. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2019;4:389–98.

Figures

Figure 1

A Markov model of non-alcoholic fatty liver disease. CC compensated cirrhosis, DC decompensated cirrhosis, F0 fibrosis stage 0/ no fibrosis, F1 fibrosis stage 1, F2 fibrosis stage 2, F3 fibrosis stage 3, F4 fibrosis stage 4, HCC hepatocellular carcinoma, LT liver transplantation, Post-LT post-liver transplantation, TP transitional probability

Figure 2

Probabilistic sensitivity analysis (PSA) represented by box plots showing the median, 25th percentile, 75th percentile, and outlier cost of NASH with significant fibrosis of each age group (\$) (A) total lifetime costs (B) lifetime cost per case

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [BMCSupplementary.docx](#)